Clinigen shakes up top personnel to support growth plan
PHARMACEUTUCAL company Clinigen Group has made organisational changes to “scale-up in line with its five year growth strategy”.
The Burton-on-Trent firm says the changes will also and recent organic growth and the integration of two new products in its specialty pharmaceuticals business.
Shaun Chilton, formerly the chief operating officer in charge of the Clinigen CTS (clinical trial supply) and Clinigen GAP operational businesses, has been appointed chief operating officer for the group and will add management of the specialty pharmaceutical business to his responsibilities.
He will be supported in this role by the appointment of new senior vice presidents to run each of these three operating businesses.
Clinigen GAP (global access programs) will be led by Mark Corbett, formerly vice president of GAP.
Lorann Morse will become senior vice president of Clinigen CTS having joined Clinigen from Myoderm where she was director of client services. She will be based in Philadelphia and Clinigen says she brings valuable regional expertise and insight to the CTS business.
David Bryant will move from his role as business development director to head up Clinigen SP (specialty pharmaceuticals) while Anton Jenkins, previously COO of Clinigen SP, has been appointed to business development director, focusing on the further in-licensing and acquisition of new products.
Peter George, chief executive officer of Clinigen Group, said, “Over the past three years, we have seen significant organic growth of CTS and GAP and the expansion of our product portfolio with the acquisition of Cardioxane from Novartis and in-licensing of VIBATIV from Theravance.
“Now is a logical time for us to ensure we have the right infrastructure and people in place to be able to scale-up further for future growth and achieve our ambitious plans.
“I am extremely happy with these appointments; we have high quality people running our operational businesses with a wealth of sector experience.”
